Bio-Thera announced yesterday that it has partnered with Cipla Limited in a licensing agreement for its potential bevacizumab biosimilar, BAT1706, referenced on Avastin.
Bio-Thera announced yesterday that it has partnered with Cipla Limited in a licensing agreement for its potential bevacizumab biosimilar, BAT1706, referenced on Avastin.
Under the agreement, Cipla will have exclusive rights to distribute and market the drug in certain emerging markets. BAT-1706 is currently being investigated in a global phase 3 study in patients with previously untreated advanced nonsquamous non—small cell lung cancer. The reference product, Avastin, is currently approved in 6 indications ranging from metastatic colorectal cancer and recurrent glioblastoma, to non-squamous non-small cell lung cancer.
“Bio-Thera is pleased to partner with Cipla to commercialize our lead biosimilar program in select emerging markets. This partnership is an important first step towards making BAT1706, our bevacizumab biosimilar product, availability [sic] globally to help increase patient access to this important cancer therapeutic at affordable prices,” Shengfeng Li, MD, chief executive officer (CEO) of Bio-Thera, said in a statement.
Additionally, through the agreement, Bio-Thera will be responsible for development, product registration with various regulatory agencies, and commercial supply of BAT1706 out of its manufacturing facilities located in Guangzhou, China. Conversely, Cipla will be responsible for the sales and marketing of the product.
“This agreement is in keeping with Cipla’s stated intention to build a strong pipeline of biosimilars through partnerships. We are committed to working towards ensuring patients receive access to life-saving drugs. Through this partnership, Cipla will leverage its strengths in marketing to take this key oncology biosimilar to patients in need,” commented Umang Vohra, MD, global CEO of Cipla.
Bio-Thera also has 2 other potential biosimilars in development: BAT1406, a proposed adalimumab biosimilar, was accepted for regulatory review in October 2018 by the National Medical Products Administration; and BAT1806, a tocilizumab biosimilar that is currently being investigated in late stage clinical trials.
Bio-Thera intends to file BAT1706 for regulatory approval with the China National Medical Products Administration, the European Medicines Agency, and the FDA in 2020.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.